Full Press Release Details
MedTech Inc. and InfuSystem Holdings, Inc. Announce Exclusive United States Distribution Agreement with, and Minority Investment in,
ChemoMouthpiece, LLC
WORTH, TX / GlobeNewswire / September 11, 2024 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara,"
the "Company," "we," "our" or "us") (NASDAQ: SMTI), a medical technology company focused
on improving clinical outcomes and reducing healthcare expenditures in the surgical, chronic wound and skincare markets, and InfuSystem,
Inc. ("InfuSystem"), the operational subsidiary of Sanara's joint venture partner InfuSystem Holdings, Inc., announced
today the execution of an exclusive United States distribution agreement with, and minority investment in, ChemoMouthpiece, LLC ("ChemoMouthpiece").
Nixon, Sanara's CEO, stated, "Oral mucositis is a debilitating condition impacting hundreds of thousands of oncology patients
annually. ChemoMouthpiece has developed a clinically validated product with FDA 510(k) clearance that can bring relief to affected patients.
The American Medical Association has recently issued the CPT code (effective July 2024) to be applied for potential reimbursement by
physicians and payers for the use of an oral cavity device for a cryotherapy procedure in conjunction with chemotherapy. The product
aligns well with Sanara's skincare strategy, which includes the licensed collagen peptides from Tufts University that focus on
radiation dermatitis. We look forward to providing the Chemo Mouthpiece oral cryotherapy device to oncology patients undergoing
mucositis causes painful mouth ulcers, which are a common complication of chemotherapy and radiation. In the U.S., there are an estimated
500,000 - 1,000,000 patients who have oral mucositis annually and the estimated market size exceeds $600 million. SI Technologies
believes this product will show material cost reductions for oncology treatment centers, improve patient quality of life and allow for
continued treatment of cancer therapy for patients. ChemoMouthpiece is planning to publish studies in the future reinforcing the efficacy
Dilorio, InfuSystem's CEO, stated, "Sanara and InfuSystem entered into our partnership in order to bring together our combined
technical, operational and commercial strengths to deliver proprietary efficacious products to patients. We believe this exclusive agreement,
which builds on our partnership, will allow us to do that by offering the Chemo Mouthpiece
oral cryotherapy device and bringing potential relief to thousands of cancer patients suffering from oral mucositis."
Yoskowitz, ChemoMouthpiece's President and CEO stated, "We are pleased to have selected SI Technologies as our exclusive
distribution partner in the United States. We believe that InfuSystem's experienced team of seasoned oncology professionals currently
calling on approximately 3,000 U.S. cancer centers will accelerate the uptake of the Chemo Mouthpiece, bringing a much-needed option
for patients that would otherwise suffer from the debilitating effects of oral mucositis." David added, "We understand that
the executive team of SI Technologies has a long history of launching products into the oncology space, and coupled with Sanara's
ownership position in ChemoMouthpiece, we are confident that they will execute the successful launch of the Chemo
Mouthpiece oral cryotherapy device."
Capital Partners, LLC, served as the exclusive advisor to ChemoMouthpiece on this transaction.
ChemoMouthpiece, LLC
LLC is a privately held medical device company that develops and commercializes propriety oral cryotherapy products for cancer patients.
The Chemo Mouthpiece oral cryotherapy device was developed based on the personal experience of inventor, founder and CEO, David
Yoskowitz, who when diagnosed with Hodgkin's Lymphoma, experienced oral mucositis firsthand. His treatment options included ice
chips to mitigate and minimize the pain. Yet this caused nausea, was difficult to maintain in his mouth, and did not effectively cool
the entire oral cavity which led him to search for a better option. The Chemo Mouthpiece oral cryotherapy device cools down the
entire oral cavity, causing vasoconstriction, which in effect slows and reduces the flow of chemotherapy in the oral cavity, thus greatly
reducing the risk of developing oral mucositis. The cryotherapy approach has been positively studied for decades and the Chemo Mouthpiece
oral cryotherapy device has significant and improved advantages over conventional cryotherapy interventions. For more information on
ChemoMouthpiece, LLC, please visit its website at www.chemomouthpiece.com.
MedTech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical
outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. The Company markets, distributes and
develops surgical, wound and skincare products for use by physicians and clinicians in hospitals, clinics and all post-acute care settings
and offers wound care and dermatology virtual consultation services via telemedicine. Sanara's products are primarily sold in the
North American advanced wound care and surgical tissue repair markets. Sanara markets and distributes CellerateRX Surgical
Activated Collagen, FORTIFY TRG Tissue Repair Graft and FORTIFY FLOWABLE Extracellular Matrix as well
as a portfolio of advanced biologic products focusing on ACTIGENTM Verified Inductive Bone Matrix, ALLOCYTE
Plus Advanced Viable Bone Matrix, BiFORM Bioactive Moldable Matrix, TEXAGEN Amniotic Membrane Allograft,
and BIASURGE Advanced Surgical Solution to the surgical market. In addition, the following products are sold in the wound
care market: BIAKOS Antimicrobial Skin and Wound Cleanser, BIAKOS Antimicrobial Wound Gel,
and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. Sanara's pipeline also contains potentially
transformative product candidates for mitigation of opportunistic pathogens and biofilm, wound re-epithelialization and closure, necrotic
tissue debridement and cell compatible substrates. The Company believes it has the ability to drive its pipeline from concept to preclinical
and clinical development while meeting quality and regulatory requirements. Sanara is constantly seeking long-term strategic partnerships
with a focus on products that improve outcomes at a lower overall cost.
InfuSystem Holdings, Inc.
Holdings, Inc. (NYSE American: INFU), is a leading national health care service provider, facilitating outpatient care for durable medical
equipment manufacturers and health care providers. INFU services are provided under a two-platform model. The first platform is Patient
Services, providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical
equipment and services. The Patient Services segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second
platform, Device Solutions, supports the Patient Services platform and leverages strong service orientation to win incremental business
from its direct payer clients. The Device Solutions segment is comprised of direct payer rentals, pump and consumable sales, and biomedical
services and repair. Headquartered in Rochester Hills, Michigan, the Company delivers local, field-based customer support and also operates
Centers of Excellence in Michigan, Kansas, California, Massachusetts, Texas and Ontario, Canada.
about Forward-Looking Statements
statements in this press release that do not constitute historical facts are "forward-looking statements," within the meaning
of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. These statements may be identified
by terms such as "aims," "anticipates," "believes," contemplates," "continue,"
"could," "estimates," "expect," "forecast," "guidance," "intend,"
"may," "plan," "possible," "potential," "predicts," "preliminary,"
"projects," "seeks," "should," "targets," "will" or "would,"
or the negatives of these terms, variations of these terms or other similar expressions. These forward-looking statements include, among
others, statements regarding the ability to market and distribute the Chemo Mouthpiece device. These items involve risks, contingencies
and uncertainties such as the ability to penetrate oncology hospitals and clinics, the extent of product demand, market and customer
acceptance, the effect of economic conditions, competition, pricing, uncertainties associated with the development and process for obtaining
regulatory approval for new products, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties
detailed in the Company's SEC filings, which could cause the Company's actual operating results, performance or business
plans or prospects to differ materially from those expressed in, or implied by these statements.
forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to revise any of
these statements to reflect the future circumstances or the occurrence of unanticipated events, except as required by applicable securities
Nichols, Director of Investor Relations